OBJECTIVE: To describe a single-center experience of pediatric intestinal transplantation (Itx) and to provide an overview of the children who underwent this procedure along with their outcomes. SUMMARY BACKGROUND DATA: Pediatric Itx presents multiple challenges because of the very young ages at which patients require transplantation and their higher susceptibility to infectious complications. METHODS: We have performed 141 Itx in 123 children with a median age of 1.37 years. Primary grafts included isolated intestine (n = 28), liver and intestine (n = 27), multivisceral (n = 61), and multivisceral without the liver (n = 7). Two protocol modifications were introduced in 1998: daclizumab induction and frequent rejection surveillance. In 2001, indications for multivisceral transplantation were expanded, and induction with Campath-1H was introduced. RESULTS: Actuarial patient survival at 1 and 3 years for group 1 (January 1994 to December 1997, n = 25), group 2 (January 1998 to March 2001, n = 29), group 3a (April 2001 to present, daclizumab, n = 51), and group 3b (April 2001 to present, Campath-1H, n = 18) was 44%/32%, 52%/38%, 83%/60%, and 44%/44%, respectively (P = 0.0003 in favor of group 3a). Severe rejection implied a dismal prognosis (65% mortality at 6 months). Observed incidence of severe rejection in groups 1, 2, 3a, and 3b was 32%, 24%, 14%, and 11%, respectively. In multivariable analysis, use of a multivisceral (with or without liver) transplant (P = 0.002), induction with daclizumab (P = 0.005), patient at home prior to transplant (P = 0.007), and age at transplant > or =1 year (P = 0.02) favorably influenced patient survival. Multivisceral transplant was protective with respect to the mortality rate due to rejection, while an older age at transplant was associated with both a lower incidence rate of developing respiratory infection and lower risk of mortality following the respiratory infection. Survivors are off parenteral nutrition and have demonstrated significant growth catch-up. CONCLUSIONS: Itx in children still is a high-risk procedure but has now become a viable option for children who otherwise have no hope for survival. Control of respiratory infection is of particular importance in the younger children.
OBJECTIVE: To describe a single-center experience of pediatric intestinal transplantation (Itx) and to provide an overview of the children who underwent this procedure along with their outcomes. SUMMARY BACKGROUND DATA: Pediatric Itx presents multiple challenges because of the very young ages at which patients require transplantation and their higher susceptibility to infectious complications. METHODS: We have performed 141 Itx in 123 children with a median age of 1.37 years. Primary grafts included isolated intestine (n = 28), liver and intestine (n = 27), multivisceral (n = 61), and multivisceral without the liver (n = 7). Two protocol modifications were introduced in 1998: daclizumab induction and frequent rejection surveillance. In 2001, indications for multivisceral transplantation were expanded, and induction with Campath-1H was introduced. RESULTS: Actuarial patient survival at 1 and 3 years for group 1 (January 1994 to December 1997, n = 25), group 2 (January 1998 to March 2001, n = 29), group 3a (April 2001 to present, daclizumab, n = 51), and group 3b (April 2001 to present, Campath-1H, n = 18) was 44%/32%, 52%/38%, 83%/60%, and 44%/44%, respectively (P = 0.0003 in favor of group 3a). Severe rejection implied a dismal prognosis (65% mortality at 6 months). Observed incidence of severe rejection in groups 1, 2, 3a, and 3b was 32%, 24%, 14%, and 11%, respectively. In multivariable analysis, use of a multivisceral (with or without liver) transplant (P = 0.002), induction with daclizumab (P = 0.005), patient at home prior to transplant (P = 0.007), and age at transplant > or =1 year (P = 0.02) favorably influenced patient survival. Multivisceral transplant was protective with respect to the mortality rate due to rejection, while an older age at transplant was associated with both a lower incidence rate of developing respiratory infection and lower risk of mortality following the respiratory infection. Survivors are off parenteral nutrition and have demonstrated significant growth catch-up. CONCLUSIONS: Itx in children still is a high-risk procedure but has now become a viable option for children who otherwise have no hope for survival. Control of respiratory infection is of particular importance in the younger children.
Authors: K Abu-Elmagd; J Reyes; G Bond; G Mazariegos; T Wu; N Murase; R Sindhi; D Martin; J Colangelo; M Zak; D Janson; M Ezzelarab; I Dvorchik; M Parizhskaya; M Deutsch; A Demetris; J Fung; T E Starzl Journal: Ann Surg Date: 2001-09 Impact factor: 12.969
Authors: Tomoaki Kato; Naveen Mittal; Seigo Nishida; David Levi; Noriyo Yamashiki; Barbara Miller; Monica Gonzalez; Phillip Ruiz; Juan Madariaga; Jose Nery; Barry Gelman; John Thompson; Anthony Gyamfi; Andreas Tzakis Journal: J Pediatr Surg Date: 2003-02 Impact factor: 2.545
Authors: Thierry Berney; Spiros Delis; Tomoaki Kato; Seigo Nishida; Naveen K Mittal; Juan Madariaga; David Levi; Jose R Nery; Robert E Cirocco; Barry Gelman; Philip Ruiz; Andreas G Tzakis Journal: Transplantation Date: 2002-10-15 Impact factor: 4.939
Authors: Akinlolu O Ojo; Philip J Held; Friedrich K Port; Robert A Wolfe; Alan B Leichtman; Eric W Young; Julie Arndorfer; Laura Christensen; Robert M Merion Journal: N Engl J Med Date: 2003-09-04 Impact factor: 91.245
Authors: Carol Pineda; Tristan Grogan; James A Lin; Joshua J Zaritsky; Robert Venick; Douglas G Farmer; Robert B Kelly Journal: Pediatr Transplant Date: 2015-03-26
Authors: Ibtesam A Hilmi; Raymond M Planinsic; Ramona Nicolau-Raducu; Daniela Damian; Ali Al-Khafaji; Tetsuro Sakai; Kareem Abu-Elmagd Journal: World J Transplant Date: 2013-12-24
Authors: Anastasia L Hryhorczuk; Heung Bae Kim; Marian H Harris; Sara O Vargas; David Zurakowski; Edward Y Lee Journal: Pediatr Radiol Date: 2015-03-22
Authors: K A Schall; K A Holoyda; C N Grant; D E Levin; E R Torres; A Maxwell; H A Pollack; R A Moats; M R Frey; A Darehzereshki; D Al Alam; C Lien; T C Grikscheit Journal: Am J Physiol Gastrointest Liver Physiol Date: 2015-06-18 Impact factor: 4.052
Authors: Tomoaki Kato; Andreas G Tzakis; Gennaro Selvaggi; Jeffrey J Gaynor; Hidenori Takahashi; James Mathew; Rolando Garcia-Morales; Erick Hernandez; Andre David; Seigo Nishida; David Levi; Jang Moon; Eddie Island; Gary Kleiner; Phillip Ruiz Journal: Ann Surg Date: 2007-09 Impact factor: 12.969
Authors: Erik R Barthel; Allison L Speer; Daniel E Levin; Frédéric G Sala; Xiaogang Hou; Yasuhiro Torashima; Clarence M Wigfall; Tracy C Grikscheit Journal: J Vis Exp Date: 2012-12-01 Impact factor: 1.355